{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:16:09Z","timestamp":1781010969986,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.msard.2023.104771","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:55:59Z","timestamp":1684756559000},"page":"104771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Safety evaluations of offspring breastfed by mothers receiving glatiramer acetate for relapsing multiple sclerosis"],"prefix":"10.1016","volume":"75","author":[{"given":"Andrea I.","family":"Ciplea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kurzeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Haben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Adamus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-9011","authenticated-orcid":false,"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104771_bib0001","unstructured":"Alemtuzumab (Lemtrada\u00ae). Summary of product characteristics. September 2018. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lemtrada-epar-product-information_en.pdf last accessed 31 January 2023."},{"key":"10.1016\/j.msard.2023.104771_bib0002","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6527458","article-title":"Management of multiple sclerosis in the breastfeeding mother","author":"Almas","year":"2016","journal-title":"Mult. Scler. Int."},{"issue":"13","key":"10.1016\/j.msard.2023.104771_bib0003","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1080\/14656566.2020.1774554","article-title":"Pharmacotherapeutic considerations in women with multiple sclerosis","volume":"21","author":"Andersen","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"issue":"10","key":"10.1016\/j.msard.2023.104771_bib0004","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1177\/13524585221083982","article-title":"Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis \u2013 COBRA study","volume":"28","author":"Ciplea","year":"2022","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2023.104771_bib0005","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1212\/NXI.0000000000000757","article-title":"Safety of potential breastmilk exposure to IFN-\u03b2 or glatiramer acetate: one-year infant outcomes","volume":"7","author":"Ciplea","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104771_bib0006","unstructured":"Cladribine (Mavenclad\u00ae). Summary of product characteristics. August 2017. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf last accessed 31 January 2023."},{"issue":"12","key":"10.1016\/j.msard.2023.104771_bib0007","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/ene.13745","article-title":"Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study","volume":"25","author":"D'Amico","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.104771_bib0008","unstructured":"Dimethyl fumarate (Tecfidera\u00ae). Summary of product characteristics. September 2018. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecfidera-epar-product-information_en.pdf last accessed 31 January 2023."},{"issue":"2","key":"10.1016\/j.msard.2023.104771_bib0009","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2023.104771_bib0010","unstructured":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis, 2021 presented at ECTRIMS 13-15 Oct 2021, virtual event https:\/\/www.medscape.com\/viewarticle\/961161."},{"key":"10.1016\/j.msard.2023.104771_bib0011","unstructured":"Fingolimod (Gilenya\u00ae). Summary of product characteristics. November 2020. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gilenya-epar-product-information_en.pdf last accessed 31 January 2023."},{"issue":"11","key":"10.1016\/j.msard.2023.104771_bib0012","first-page":"969","article-title":"Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series","volume":"24","author":"Fragoso","year":"2010","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.msard.2023.104771_bib0013","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12887-019-1693-2","article-title":"The relationship between breastfeeding and reported respiratory and gastrointestinal infection rates in young children","volume":"19","author":"Frank","year":"2019","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.msard.2023.104771_bib0014","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104771_bib0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2377-12-124","article-title":"Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study","volume":"12","author":"Giannini","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2023.104771_bib0016","unstructured":"Glatiramer acetate (Copaxone\u00ae). Summary of product characteristics. February 2022. Available on https:\/\/www.medicines.org.uk\/emc\/product\/183#gref last accessed 31 January 2023."},{"key":"10.1016\/j.msard.2023.104771_bib0017","unstructured":"Greiner W., Batram M., Scholz S., Witte J. Kinder- und jugendreport nordrhein-westfalen gesundheitsversorgung von kindern- und jugendlichen in nordrhein-westfalen; February 2019. Available on https:\/\/www.dak.de\/dak\/download\/download-kinder\u2013und-jugendreport-2019-nordrhein-westfalen-2106266.pdf last accessed 31 January 2023."},{"issue":"2","key":"10.1016\/j.msard.2023.104771_bib0018","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/bfm.2011.0044","article-title":"Transfer of interferon \u03b2-1a into human breastmilk","volume":"7","author":"Hale","year":"2012","journal-title":"Breastfeed. Med."},{"key":"10.1016\/j.msard.2023.104771_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211051012","article-title":"A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis","volume":"14","author":"Hellwig","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.msard.2023.104771_bib0020","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/1352458515623366","article-title":"Glatiramer acetate during early pregnancy: a prospective cohort study","volume":"22","author":"Herbstritt","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104771_bib0021","doi-asserted-by":"crossref","first-page":"e1559","DOI":"10.1212\/WNL.0000000000006384","article-title":"Pregnancy rates and outcomes in women with and without MS in the United States","volume":"91","author":"Houtchens","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104771_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103700","article-title":"Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients","volume":"60","author":"Houtchens","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104771_bib0023","unstructured":"Kaplan S., Zeygarnik M., Stern T. 2021 Pregnancy and foetal outcomes and breastfeeding practices following maternal exposure to glatiramer acetate. Poster presented at ECTRIMS 2021 (13\u20135 October; virtual congress). Poster P179."},{"key":"10.1016\/j.msard.2023.104771_bib0024","unstructured":"Interferon (Rebif\u00ae). Summary of product characteristics. May 2008. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rebif-epar-product-information_en.pdf accessed 31 January 2023."},{"issue":"3","key":"10.1016\/j.msard.2023.104771_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/jamaneurol.2019.4173","article-title":"Association between breastfeeding and postpartum multiple sclerosis relapses: a Systematic Review and Meta-analysis","volume":"77","author":"Krysko","year":"2020","journal-title":"JAMA Neurol."},{"issue":"18","key":"10.1016\/j.msard.2023.104771_bib0026","doi-asserted-by":"crossref","first-page":"e1939","DOI":"10.1212\/WNL.0000000000009374","article-title":"Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort","volume":"94","author":"Langer-Gould","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2023.104771_bib0027","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","article-title":"Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"267","author":"Li","year":"2020","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.104771_bib0028","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/BOR.0b013e32832a2e16","article-title":"Environmental influences on risk for rheumatoid arthritis","volume":"21","author":"Liao","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"issue":"7","key":"10.1016\/j.msard.2023.104771_bib0029","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/jnnp-2022-328994","article-title":"Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis","volume":"93","author":"Magyari","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2023.104771_bib0030","unstructured":"Natalizumab (Tysabri\u00ae). Summary of product characteristics. April 2016. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf last accessed 31 January 2023."},{"key":"10.1016\/j.msard.2023.104771_bib0031","unstructured":"Ocrelizumab (Ocrevus\u00ae). Summary of product characteristics. January 2018. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf last accessed 31 January 2023."},{"key":"10.1016\/j.msard.2023.104771_bib0032","unstructured":"Ofatumumab (Kesimpta\u00ae). Summary of product characteristics. March 2021. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf last accessed 31 January 2023."},{"key":"10.1016\/j.msard.2023.104771_bib0033","unstructured":"Ozanimod (Zeposia\u00ae). Summary of product characteristics. May 2020. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zeposia-epar-product-information_en.pdf last accessed 31 January 2023."},{"key":"10.1016\/j.msard.2023.104771_bib0034","unstructured":"Ponesimod (Ponvory\u00ae). Summary of product characteristics. May 2021. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ponvory-epar-product-information_en.pdf last accessed 31 January 2023."},{"issue":"1","key":"10.1016\/j.msard.2023.104771_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7224\/1537-2073.2016-079","article-title":"Pregnancy outcomes from the branded glatiramer acetate pregnancy database","volume":"20","author":"Sandberg-Wollheim","year":"2018","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2023.104771_bib0036","unstructured":"Siponimod (Mayzent\u00ae). Summary of product characteristics. January 2020. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mayzent-epar-product-information_en.pdf last accessed 31 January 2023."},{"key":"10.1016\/j.msard.2023.104771_bib0037","unstructured":"Terflunomide (Aubagio\u00ae). Summary of product characteristics. May 2018. Available on https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aubagio-epar-product-information_en.pdf last accessed 31 January 2023."},{"key":"10.1016\/j.msard.2023.104771_bib0038","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211054956","article-title":"The german multiple sclerosis and pregnancy registry: rationale, objective, design, and first results","volume":"14","author":"Thiel","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.msard.2023.104771_bib0039","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14740338.2017.1311321","article-title":"Treatment of multiple sclerosis during pregnancy - safety considerations","volume":"16","author":"Th\u00f6ne","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"10.1016\/j.msard.2023.104771_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/medicina56020049","article-title":"Pregnancy and multiple sclerosis: an update on the disease modifying treatment strategy and a review of pregnancy's impact on disease activity","volume":"56","author":"Varyt\u0117","year":"2020","journal-title":"Medicina"},{"issue":"Pt 6","key":"10.1016\/j.msard.2023.104771_bib0041","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/brain\/awh152","article-title":"Pregnancy in multiple sclerosis group. pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse","volume":"127","author":"Vukusic","year":"2004","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2023.104771_bib0042","first-page":"368","article-title":"Breastfeeding: common questions and answers","volume":"98","author":"Westerfield","year":"2018","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.msard.2023.104771_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"\u2018Multiple sclerosis therapy consensus group\u2019 (MSTCG). multiple sclerosis therapy consensus group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104771_bib0044","unstructured":"World Health Organization. Fact sheet: infant and young child feeding. June 2021. Available on https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/infant-and-young-child-feeding last accessed 31 January 2023."},{"issue":"2","key":"10.1016\/j.msard.2023.104771_bib0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/nmt-2021-0031","article-title":"Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany","volume":"12","author":"Ziemssen","year":"2022","journal-title":"Neurodegener. Dis. Manag."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:24Z","timestamp":1761901644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823002730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":45,"alternative-id":["S2211034823002730"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104771","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety evaluations of offspring breastfed by mothers receiving glatiramer acetate for relapsing multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104771"}}